InVivo Therapeutics Appoints Biz-Dev V.P.

InVivo Therapeutics Holdings Corporation, a Cambridge, Mass.-based biomaterials company the makes technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that Christopher McNulty has been appointed as vice president, business development.

Most recently, McNulty served as senior director of business development at Repligen Corporation, where his responsibilities included out-licensing programs for rare neurodegenerative diseases. Previously, he was director of corporate development at Seventh Sense Biosystems and associate director of business development and alliance management at Genzyme Corporation. While at Genzyme, he led business development activities in the area of neurology. Before joining Genzyme, McNulty held technical roles at Transform Pharmaceuticals and Cereon Genomics. He has an MBA from Harvard Business School, and BS and MEng degrees from Massachusetts Institute of Technolofy, where he performed research on biological hydrogels.

“Going forward we expect our growth to be driven primarily by our success as a drug delivery company,” said Michael Astrue, the interim CEO of InVivo. “In particular, our proprietary technology that can deliver proteins and other molecules locally on a time-release basis can provide significant value to most major pharmaceutical companies and biotech companies. Chris will be a key part of our transformation.”

InVivo focuses on using polymers as a platform technology to develop treatments for serious diseases and conditions, including improving function in individuals paralyzed as a result of traumatic spinal cord injury.